BCRX Biocryst Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 32

Relative Strength: Rel. Strength: 46

Relative Valuation: Rel. Valuation: 19

Relative Profitability: Rel. Profitability: 18

EPS in 2026 (TTM): -$1.73

Last Report Period Date: Mar 31, 2026

As of June this year, based on Biocryst Pharmaceuticals's most recent financial report, the company's trailing twelve months EPS is -$1.73. During 2025, BCRX reported a per-share earnings of $1.26, which shows a rise compared to the EPS of -$0.43 recorded in 2024. Biocryst Pharmaceuticals's EPS for the quarterly period ending on Mar 31, 2026 came in at -$2.98.

BCRX earnings history

Historical annual and quarterly earnings per share (EPS) data for Biocryst Pharmaceuticals

EPS (TTM)

-$1.73

EPS Growth YoY (Quarterly)

N/A

EPS (Quarterly)

-$2.98

EPS Growth (Quarterly)

-354.7%

The yearly earnings per share during 2025 was $1.26, a rise of 393% compared to -$0.43 recorded in 2024. As of March 2026, the TTM EPS is -$1.73. During 2024, the annual earnings per share was -$0.43, representing an increase of 63.6% compared to 2023.

BCRX earnings chart

BCRX EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

N/A

EPS growth YoY

393%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

BCRX Earnings Waterfall

Breakdown of revenue, profit and net income for Biocryst Pharmaceuticals

BCRX Earnings vs Peers

What are the earnings of BCRX compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
GILD Gilead Sciences Inc	16.85	1,700%	23.2%	132.8%
SRPT Sarepta Therapeutics Inc	28.77	-388.7%	N/A	N/A
RGEN Repligen Corp	137.36	289.1%	-36.2%	-5.3%
NNVC Nanoviricides Inc	N/A	10%	N/A	N/A
NVAX Novavax Inc	N/A	321.1%	N/A	N/A
CLDX Celldex Therapeutics Inc	N/A	-59.2%	N/A	N/A
EBS Emergent BioSolutions Inc	N/A	127.2%	N/A	-29.9%
CVM Cel Sci Corp	N/A	59%	N/A	N/A
BCRX Biocryst Pharmaceuticals Inc	N/A	393%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.